ratory disease in the late 1960s. 25 The NMK7 isolate of BRSV was recovered during the outbreak, passed 11 times in bovine kidney cells, and then inoculated into a calf by both intranasal (20 ml) and intratracheal (10 ml) routes. Tissue culture fluid used as an inoculum contained 10 3.8 median tissue culture infective doses (TCID 50 ) of BRSV/0.1 ml. Pyrexia (39.8-41 .3 C), anorexia, depression, lacrimation, and serous nasal discharge characterized the calf s respiratory tract illness subsequent to inoculation. Leukopenia was observed on the second day postinoculation (PI) and by day 9 PI, all clinical signs were resolved. Virus was recovered from nasal secretions on days 5, 6, 7, 9, and 10 PI. Neutralizing antibodies against the virus were detected at 2 weeks PI. The viral inocula were not screened for the presence of bovine viral diarrhea virus (BVDV).
In 1971, BRSV was isolated from a herd of Iowa feedlot cattle with acute respiratory disease. 5o Five 8-week-old calves were inoculated via intranasal aerosolization of 4 ml of inoculum containing approximately 4,000 plaque-forming units (PFU) of 18th passage virus. Clinical signs of pyrexia (40 C), polypnea, anorexia, serous nasal discharge, and depression were observed in 2 of 5 calves on day 4 PI. Another calf displayed depression and anorexia, and the 2 remaining calves, which were seronegative to BRSV at the time of experimental inoculation, displayed no clinical signs of BRSV. Prior to inoculation, maternal antibody to BRSV was identified only in those calves that developed illness PI, suggesting that calves may be similar to human infants who have maternal antibody to RSV and experience the most severe respiratory disease. 13 The isolation of BRSV from cattle in Norway was also followed by an experimental study in a calf using the recovered isolate. 41 The animal developed mild clinical disease, virus was reisolated from the upper respiratory tract, and production of antibodies was demonstrated.
In another study, 3 isolates (Dorset, Hertfordshire, and Swiss) of BRSV were intranasally or intratrach-eally administered to conventionally reared, colostrum-deprived, and gnotobiotic calves. 26 One isolate of HRSV was administered intranasally to a gnotobiotic calf. Generally, 10 ml of BRSV or HRSV inoculum ( 10 5.5 -10 7.6 TCID 50 , third to seventh passage) was administered to calves ranging in age from 3 to 14 weeks. Clinical signs in BRSV-inoculated calves were observed in 5 of 7 conventionally raised calves, 1 of 9 colostrum-deprived calves, and 4 of 6 gnotobiotic calves. Clinical signs were mild and included pyrexia (biphasic in 3), lethargy, nasal discharge, and cough. Because bronchopneumonia was present prior to inoculation, results in 4 conventionally raised calves were questionable. The calf inoculated with HRSV had a biphasic pyrexia. Virus was isolated from nasal secretions of most calves at 4-10 days PI and from respiratory tract mucosa, tonsil, and lung in other calves at necropsy. No gross lesions were observed in experimentally infected calves. Histopathologic changes in 12 calves consisted of catarrhal bronchiolitis and occasional syncytial cells. Virus was isolated only from nasal secretions on day 5 PI from the HRSV-inoculated calf. This calf seroconverted by day 10 PI, and although no gross lesions indicative of HRSV were observed, microscopic lesions included epithelial necrosis in turbinates and trachea.
Serum antibody titers were determined by a serum neutralization test and results indicated that infection can occur despite the presence of circulating antibodies. Also, passively derived maternal antibody did not cause disease exacerbation as had been reported previously. 50 Clinical signs and pathologic changes in this study were milder than responses observed in field cases of BRSV. Differences in viral isolate, passage level, titer of inocula, or cell culture system did not alter the clinical responses observed in experimentally infected calves. Laboratory reproduction of the condition as observed in the field may require additional factors other than virus. 26 In the first controlled BRSV experimental study, 6-8-week-old calves were inoculated by intranasal aerosolization, intratracheal, or both routes. 36 Ten milliliters of 11th passage inoculum (10 3.5 TCID 50 /ml, isolate Bov X) was utilized for each route. All calves displayed mild clinical signs, including transient temperature elevation, slight serous nasal discharge, mild cough, and slight hyperpnea. Virus was isolated from all infected calves after day 7 PI. Minimal serologic response was measured by neutralizing antibody titers in serum and nasal secretions. Mild pulmonary consolidation was observed grossly, whereas interstitial pneumonia, syncytial cells, squamous metaplasia of bronchiolar epithelium, and bronchial lymph node hyperplasia were observed as histopathologic. changes. Control calves remained normal throughout the study.
An additional study by the same authors examined the role of serum and mucosal antibodies on the outcome of experimental BRSV infections. 37 In this second study, 6-8-week-old calves were inoculated with 10 ml of viral inocula (isolate A 51908, fifth passage, 10 3.5 TCID 50 /ml) intranasally and 10 ml intratracheally. A transient temperature increase, slight serous nasal discharge, mild cough, and slight hyperpnea were observed in all but 1 calf after the first inoculation. Control calves remained normal. Five weeks PI, calves were reinoculated intranasally and intratracheally with virus. Clinical signs of respiratory disease were not observed after the second inoculation. Virus was isolated from nasal secretions of all calves after initial BRSV inoculation and from 3 of 5 calves after reexposure. Recovery of virus was enhanced by inoculating cells with nasal secretion within an hour of collection. Gross lesions and histopathologic changes were equivalent to those reported in the previous study. 36 Prior to initial inoculation in the above study, all calves possessed serum neutralizing antibody titers (1:2 to 1:16) to BRSV, but only 1 calf had detectable levels of neutralizing antibody in nasal secretions. 37 Inoculated calves responded serologically, but their titers of serum neutralizing (1:2 to 1:32) and nasal secretory antibody remained low. Following reinoculation, calves responded with high titers of both serum neutralizing (1:8 to 1:128) and secretory (1:8 to 1:16) antibody. Three control calves not inoculated with BRSV during the initial exposure were inoculated during the second exposure and had elevated rectal temperature, mild cough, and hyperpnea compatible with BRSV-induced disease, indicating that BRSV could induce disease in the presence or absence of circulating serum antibodies. Unlike previous reports in humans 13, 28 and cattle, 5o there was no indication that presence of serum antibody to BRSV exacerbated the severity of disease in young calves. 26 The presence of nasal secretory antibody to BRSV apparently offered protection to calves reinoculated with virus.
Experimental infectivity studies were conducted in 2 groups of calves by researchers at the University of Saskatchewan. 38 One-week-old and 7-month-old calves determined to be free of serum neutralizing antibodies against BRSV were inoculated intranasally with the Iowa isolate (FSI-1) of BRSV. Two milliliters of virus (10 5 PFU/ml) were aerosolized into nasal passages. The majority of calves in each group exhibited increased lung sounds, coughing, mucopurulent nasal discharge, pyrexia (39.4-39.7 C), and ocular discharge. Virus was isolated from the nasal cavities of most calves. Oneweek-old calves were euthanized at 3-day intervals following inoculation, but no gross or histologic lesions were observed. Because of the inability to reproduce severe respiratory disease with morphologic lesions, the role of BRSV in the bovine respiratory disease complex was questioned by these investigators.
Prior to the late 197Os, BRSV inoculation studies in calves resulted in mild clinical disease. To more accurately assess mild respiratory disease, an experimental BRSV inoculation study adapted an unbiased quantitative scoring system to use in conjunction with experimental infections. 57 Disease scores were generated for each animal based on clinical observations and hematologic measurements, and resulting scores were compared between principal and control groups of calves. Intense monitoring of these calves provided evidence that allowed investigators to determine that the BRSV inoculum was contaminated with BVDV. In previous studies, screening for BVDV in the inocula was seldom mentioned. The scoring system utilized for this project failed to gain wide acceptance by later investigators. 20, 54 In 1 study, 54 calves were experimentally inoculated with BRSV, and clinical signs were graded to calculate an illness score for each animal. Serum antibody response and virus isolation from nasal secretions indicated that infection was established. There was no evidence that experimental BRSV inoculation produced disease, because mean illness scores were not significantly different between infected and control calves. The authors concluded that BRSV could still have a causative role in the bovine respiratory disease complex if the appropriate conditions for the pathogen were present at the onset of infection.
A Canadian study was the first to report moderate to severe signs of respiratory disease following experimental inoculation with BRSV. 20 The 1-5-week-old calves were inoculated intranasally by aerosolization with the Quebec isolate of BRSV (2 x 10 6 TCID 50 /10 ml). These animals were scored on the basis of ocular discharge, conjunctivitis, lung sounds, nasal discharge, pyrexia, and leukopenia. Highest disease scores were observed between 6 and 9 days PI, and scores were much higher in infected calves than in controls. Responses were characterized as moderate in 2 infected calves and as severe in 9 other infected calves. Inoculated calves shed BRSV in their nasal secretions from 1 to 12 days PI. At 6 days PI, infected calves seroconverted to BRSV; the highest antibody titer was 1:128. No reference was made to screening the BRSV inoculum for the presence of BVDV.
In another Canadian study, calves were inoculated with BRSV and interferon, and serum-antibody responses were characterized; additional groups of calves were rechallenged on day 15 or 37 PI. 21 Six-week-old calves that were seronegative for BRSV were given the Quebec isolate of BRSV (2 x 10 5 TCID 50 ). Inoculum (10 ml) was administered via aerosolization through an endotracheal tube that was adjusted to give a par-title size of 0.5-3 µm. All BRSV-inoculated calves developed conjunctivitis, lacrimation, increased lung sounds, dyspnea, and pyrexia (39-41 C) . Clinical signs peaked at 6-7 days PI, with signs subsiding and disappearing by day 9 PI. In groups of calves reinoculated with BRSV, no signs of disease were observed following secondary challenge. Control calves displayed no signs of respiratory tract disease throughout the study. After initial inoculation, serum antibody as measured by indirect fluorescent antibody test was detected at day 3 PI, peaked at approximately day 10 PI, and remained stable for at least 7.5 weeks before decreasing. The serum neutralization technique was used to detect serum antibody to BRSV, with peak titers occurring at 4-5 weeks PI. Higher titers were consistently obtained with the indirect fluorescent antibody test than with the serum neutralization test. BRSV antibodies were not detected in sera of control calves, and no anamnestic response was observed after rechallenge of infected calves. Interferon titers, measured by a plaque-inhibition technique, peaked in the early stage of infection, were decreased by day 6 PI, and then reappeared at moderate to low levels and persisted for weeks. Interferon was not detected in sera from control calves. Although no clinical signs of disease were noted after rechallenge, virus was detected until day 9 PI, indicating that reinfection did occur.
In another study, direct immunofluorescence and virus isolation procedures were compared as diagnostic techniques for experimental BRSV infections in conventional calves. 55 The 5-9-month-old calves were inoculated intranasally with 5 ml of BRSV inoculum ( 1.9 x 10 5 PFU/ml). Virus isolation was most sensitive between 3 and 9 days PI, with 21/107 nasopharyngeal specimens yielding positive results. Immunofluorescence was more sensitive between 10 and 17 days PI, with 24/107 samples positive by the direct fluorescent antibody test. In an addendum to this study, gnotobiotic calves were inoculated with BRSV. Lung sections were stained by a direct immunofluorescent method for BRSV antigen and were positive in 8 of 9 calves, with antigen detected up to 48 hours postmortem. Virus isolation from nasopharyngeal swabs was used to confirm the presence of BRSV. BRSV was recovered from lung washings from only 2 calves. The direct immunofluorescence testing was considered a reliable, quick, and easy method of successfully diagnosing BRSV infection from nasopharyngeal and lung samples. Nonspecific fluorescence occasionally made interpretation of nasopharyngeal smears difficul was not a problem with lung tissue samples.
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To date, the most successful attempt to experimentally reproduce respiratory tract disease in calves with BRSV took place in Northern Ireland in 1982. 10, 35 A local isolate of BRSV (10 3.5 -10 6.5 TCID 50 of virus/ml) was used to inoculate 3-6-day-old colostrum-deprived calves that had received intravenous bovine immunoglobulin. One group of calves were inoculated in the morning using 10 ml of virus intranasally and intratracheally, followed by 10 ml of virus intranasally each evening for 4 consecutive days. Another group of calves were inoculated intranasally with 10 ml of virus, moming and afternoon, for 4 consecutive days. Control calves were inoculated as described for the first group, only using medium from noninfected cell cultures. Calves were examined daily and were serially necropsied on days 1-13 PI. Calves inoculated by the combined route developed a severe respiratory tract disease characterized by coughing, tachypnea, hyperpnea, and harsh lung sounds. Rectal temperatures never exceeded 39.4 C. Clinical disease was less severe in intranasally inoculated calves, and control calves remained clinically normal. Calves inoculated by the combined route exhibited confluent and extensive areas of consolidation primarily in cranial, middle, and cranioventral portions of the caudal lung lobes. Numerous epithelial syncytia were first observed on day 4 PI in bronchial, bronchiolar, and alveolar walls of these calves. The pneumonia in the principal calves had an exudative and proliferative component, with the most severe damage characterized by severe bronchitis, bronchiolitis, and alveolar changes in calves euthanized on days 5, 6, and 8 PI. Gross lesions were minimal in intranasally inoculated calves; minute lesions were observed in 2/5 control calves, of which BVDV was isolated from a lesion in 1 calf. Histopathologic changes associated with BRSV in intranasally inoculated calves were less severe than those inoculated by the combined route, and lesions were not identified in control calves. Immunofluorescence demonstrated BRSV antigen in the upper and/or lower respiratory tract of intranasally and intratracheally inoculated calves, and only BRSV was isolated from the lower respiratory tract of the same calves. Neither BRSV antigen or BRSV were identified in those calves inoculated only by the intranasal route. Four of five seronegative colostrum-deprived calves seroconverted to BRSV between days 10 and 13 PI, whereas seropositive colostrum-fed calves did not demonstrate an increase in antibody levels to BRSV. The ability of these researchers to reproduce severe respiratory disease was attributed to 1) pathogenicity of the BRSV isolate (passage level 4-7); 2) inoculation by a combined respiratory route; 3) inoculation on 4 consecutive days; 4) young susceptible (seronegative) cattle; and 5) season of the year (fall inoculation). No other viruses were identified by isolation procedures.
In a study of conventionally raised l-month-old calves, ultrastructural changes, alveolar function, and cellular susceptibility to infection in the respiratory tract was seen subsequent to BRSV infection. 11, 12 Twenty-one calves were inoculated on day 37 with BRSV (isolate 375) containing between 10 4 and 10 6.9 TCID 50 /ml given by a combined intranasal (aerosolized) and intratracheal route. Six control calves were sham inoculated with uninfected tissue culture medium by the same route. Calves were serially necropsied between day 2 and 30 PI. Seven of 21 calves developed a mild respiratory infection characterized by serous nasal discharge, mild dry cough, and mild wheezing, which was more pronounced between days 3 and 5 PI. At necropsy, 1 calf displayed marked lesions, whereas other BRSV-inoculated calves and control calves had only occasional scattered red and depressed lobules in cranioventral lung areas. Extensive interstitial pneumonia was not present. However, bronchitis lesions were consistent, and rhinitis, tracheitis, and bronchiolitis were also observed. Epithelial damage consisted of necrosis, edema and neutrophil infiltration, and syncytial cell formation. The respiratory epithelium was repaired between days 17 and 30 PI.
Viral nucleocapsids and budding virions were detected in tracheal and bronchial epithelial cells by immunofluorescent techniques, most commonly 3-5 days PI. This finding was similar to that of the previous experimental study, but in addition, alveolar epithelial cells and alveolar macrophages displayed positive fluorescence for BRSV antigen. Associated with viral assembly was the loss of cilia from ciliated cells, formation of syncytial epithelial cells, swelling of mitochondria and endoplasmic reticulum, and cell necrosis. By day 5 PI, mild interstitial pneumonia was observed. By 30 days PI, pulmonary ultrastructure in BRSVinoculated calves was indistinguishable from that in controls, suggesting that BRSV-induced airway epithelial damage is reversible. The investigators proposed that virus-induced damage to airway epithelium may depress mucociliary clearance and thereby enhance susceptibility to bacterial infection. Seroconversion to BRSV was detected by serum neutralization as early as day 3 PI and was not influenced by maternal antibody to BRSV.
Phagocytosis by alveolar macrophages was evaluated in vitro by the rate of uptake of polyvinyl toluene beads. Alveolar macrophages exposed to BRSV in vivo demonstrated a significant increase in phagocytic rate in vitro on day 5 PI.
Because lesions in this study were not as severe as those observed previously, 10 differences in viral strains, viral pathogenicity, host factors, and intercurrent pulmonary bacterial and viral infections were proposed as reasons for variability in experimental BRSV infections.
An experimental study in 3-5-month-old calves investigated the influence of humoral immunity on se-verity of BRSV disease. 52 BRSV-vaccinated, nonvaccinated, and control groups of calves were utilized. Vaccinated calves received an alum-precipitated vaccine 29 and 17 days before BRSV inoculation. Inoculated calves were exposed to a 5-minute aerosolization of 5 ml of inoculum (10 7.4 TCID 50 BRSV/ml) using a nebulizer and face mask. This exposure was repeated 35 days PI. The most common signs of infection included tachypnea, abnormal lung sounds, and pyrexia. Peak clinical signs were observed by day 6 PI for the first exposure. Signs were observed again after reinoculation in both vaccinated and nonvaccinated calves, indicating that calves can be reinfected with BRSV and can display similar clinical signs even in the presence of serum antibody to BRSV. Virus was isolated usually by day 3 PI in both infected groups of calves, with the majority of isolates from nasopharyngeal swabs, fewer from serum, and less from lung lavage fluid. Less virus was recovered from vaccinated calves than from nonvaccinated calves. BRSV antigen was detected by a combination of direct fluorescent microscopy and virus isolation.
In a later study, researchers attempted reproduction of experimental BRSV infection in conventional calves. 14 Also, 1 group of calves were reinoculated with BRSV 10 days PI in an effort to reproduce BRSV's occasional biphasic disease presentation. Colostrumfed Holstein calves were obtained at 2-6 days of age and inoculated at 1 month of age. The BRSV isolate was recovered from a natural outbreak, and the titer of inoculum A (passage 5) was 10 4.9 TCID 50 BRSV/ml. Inoculum A was decanted tissue culture medium used as intranasal inoculum. Decanted tissue culture medium was replaced with a minimum essential medium containing 44% sucrose and 20% horse serum, and the infected cell culture was frozen at -70 C and thawed for 5 cycles to promote cell rupture and release of virus. The horse serum-sucrose medium served as intratracheal inoculum (10 6.3 TCID 50 BRSV/ml). Cell cultures were checked and found free of BVDV. Calves in the principal group were inoculated by a combined intratracheal/intranasal route for 4 days, employing a previously described protocol. 10 Control calves were given inocula prepared from noninfected bovine turbinate cells. Daily temperatures, heart rates, respiratory rates, and arterial blood gases were taken. One group of calves was necropsied at 4-6 days PI, 1 group was reinoculated with BRSV at 10 days PI, and this group and other BRSV-inoculated and sham-inoculated calves were necropsied at 21 days PI.
Respiratory disease was produced in each of the principal groups with signs including tachypnea, hyperpnea, dyspnea, depression, lethargy, excessive lacrimation, nasal and ocular discharges, hypersalivation, and coughing. Signs appeared 1-2 days after last in-oculation; in the reinoculated group, no signs of respiratory "disease were observed following reinoculation, a finding similar to those of previous studies. 21, 26, 36, 58 Significant decreases in PaO 2 were observed between control and principal groups on days 6-8.
All calves had maternally derived antibodies to BRSV prior to inoculation, and no calves were observed to seroconvert (4-fold or greater rise in antibody titer) to BRSV throughout the study period. Virus was isolated from nasal swabs of only 5 of 6 calves (group necropsied at day 21 PI) that were inoculated with BRSV. Direct immunofluorescence staining was used to detect BRSV antigen in frozen lung and bronchial lymph node but was unsuccessful in all calves. Immunoperoxidase staining detected BRSV antigen in lung tissue from all except control calves. 23 Macroscopic lesions occurred in all principal groups and were confined to the respiratory tract. Lesions were most severe in the group necropsied on days 4-6 PI and included hemorrhage and lobular consolidation within the cranial and middle lung lobes. One calf in this group had overinflated, emphysematous caudal lung lobes.
Microscopic lesions in 2 of 6 control calves included mild lymphomononuclear infiltrates into peribronchiolar connective tissues, presumably a reaction to the intratracheal inoculum. In the group of principal calves necropsied 4-6 days PI, lesions were severe in terminal airways, interstitial tissues, and alveolar sacs. Fibrinocellular and mixed cellular exudates were present in bronchiolar lumina, and epithelium was generally hyperplastic with occasional mitotic figures observed. Alveolar walls appeared thickened, and lumina contained a mixed-cellular inflammatory exudate. Giant cells were observed occasionally in alveolar and bronchiolar lumina. Microscopic lesions in other principal calves were similar, although the rechallenged group appeared to have a greater number of syncytial cells present. In both groups, the predominant microscopic lesion was an extensive peribronchiolar lymphomononuclear cell infiltration.
Pneumonic surface area involvement was determined by computer digitalization and was most extensive in the calves necropsied 4-6 days PI, with only moderate pneumonic surface area involvement in other principal groups.
In this study, severe respiratory disease was successfully induced in older conventionally reared calves utilizing a low-passage field isolate of BRSV. Biphasic disease did not appear in calves inoculated with BRSV and then maintained for 21 days, nor did it appear when calves were reinoculated 10 days after the initial exposure, unlike the results of the previous study. 52 The biphasic pattern is not a consistent finding in the literature. 5, 63 This study failed to support persistent viral infection or hypersensitivity reactions as mechanisms of BRSV pathogenesis. As in a previous study, which utilized calves less than 7 days of age, 10 this study indicated that dual inoculation was capable of inducing severe respiratory disease and lesions in l-month-old colostrum-fed calves. Macroscopic and microscopic lesions were more severe in those calves necropsied during the period of maximal clinical response than in those necropsied 21 days PI, in which lesions had time to resolve. Microbiologic and histologic findings did not support bacterial secondary infections as playing a major role in the reproduced disease. Quantitation of pneumonic surface lesions by computer data digitalization is more accurate than estimating percentage of lung surface with macroscopic lesions, as was done previously. 2,56,60 Pneumonic surface area, however, may not accurately correlate with total pneumonic involvement due to the presence of deep parenchymal lesions with no surface involvement.
Experimental BRSV infections in gnotobiotic and colostrum-deprived calves
In an effort to unequivocally define BRSV as a respiratory pathogen, many experimental studies were performed in gnotobiotic calves. Of 8 calves intranasally inoculated with 3,000-50,000 PFU/10 ml tissue culture medium, none developed signs of respiratory disease. 56 The Snook isolate of RSV, used at the eighth passage, was contained in the inoculum. Calves were 26-88 days of age at time of inoculation.
At necropsy, 7-14 days PI, gross lesions were noted on approximately 2-25% of the lung surface. Microscopic lesions included an exudative and proliferative bronchiolitis with accompanying alveolar collapse and infiltration of peribronchiolar tissue and alveolar walls with round mononuclear cells and some polymorphs. Multinucleate epithelial syncytia were uncommon findings. Bacterial cultures of lung homogenate did not exceed 10 2 colony-forming units (CFU)/ml. Immunofluorescence detected BRSV antigen between days 2 and 11 PI in nasopharyngeal smears, nasal mucosa, and lung sections. Highest titers of virus from the nasopharynx were detected between days 4 and 7 PI, and serum antibody to RSV was detected at day 9 PI.
In another study, researchers used BRSV and HRSV inoculates and also looked at the effect of dexamethasone treatment. 58 Thirteen gnotobiotic calves were inoculated between 10 and 71 days of age with the Compton 127 isolate of BRSV (23rd passage), and 7 calves received the human A2 strain of HRSV, also at a high passage level. Calves were inoculated by an intranasal route, intranasal and intratracheal routes, or aerosol spray. Two calves were reinoculated by aerosol spray and then intratracheally 10 days PI. Four calves were inoculated by the combined route and then re-ceived dexamethasone (0.5 mg/kg intramuscularly every 24 hours) for 10 days.
Other than the calves receiving dexamethasone, none of the inoculation procedures produced clinical signs of respiratory disease, and no significant macroscopic lesions developed in the lungs. Microscopic lesions included peribronchial tissue infiltration with round mononuclear cells.
The lungs of 3 of 4 dexamethasone-treated calves had small areas of consolidation at necropsy, with a copious mucoid exudate in the lower airways of 1 calf. Histopathology revealed infiltration of peribronchiolar tissue and alveolar walls by round mononuclear cells, a mild exudative alveolitis and bronchiolitis, and a catarrhal bronchial exudate.
Viruses (both BRSV and HRSV) were isolated on days 1-17 PI from the nasopharynx of calves. Mean duration of viral shedding and viral titer were increased in calves treated with dexamethasone. Serum antibody to RSV was detected by virus neutralization or single radial hemolysis at 1-12 days PI and by specific anti-RSV IgG at 16 days PI. Four of 13 lungs examined by direct immunofluorescence were positive for BRSV antigen, primarily in bronchial exudate.
Both HRSV and BRSV appear to have similar growth characteristics in gnotobiotic calves, as indicated by their period of viral shedding and peak titers observed. Dexamethasone treatment increased the period of viral shedding, amount of virus recovered, and probably the severity of lesions.
Antibody responses to BRSV inoculation and reinoculation was evaluated in colostrum-fed and colostrum-deprived calves. 29 Colostrum-deprived calves were inoculated at 3-4 weeks of age intratracheally (15 ml) and intranasally (2.5 ml/nostril) for 4 consecutive days. Colostrum-fed calves were inoculated similarly at 3 weeks or 10 weeks of age. The inocula contained a BRSV isolate recovered from a recent field outbreak (passage 5-6, 10 3 -10 5 TCID 50 BRSV/ml). Inocula were checked for the presence of BVDV. All calves were reinoculated after 3 or 4 months, and some were reinoculated a third time 3 months after the second inoculation. All BRSV-inoculated calves displayed signs of mild pyrexia, coughing, and abnormal lung sounds. Reinoculated and control calves did not display any clinical signs of respiratory disease.
The antibody response to BRSV in colostrum-deprived calves was detected at days 8-10 PI and consisted of BRSV-specific IgM and IgA in serum, lung lavage fluid, nasal and eye secretions, and feces. IgG 1 was next to appear in the serum, followed by IgG 2 . Reinoculation was characterized by a rapid strong response of IgA, more prominent in nasal and eye secretions than in lung lavage fluid. Colostrum-fed calves had increased serum levels of IgG 1 after colostrum feeding and mucosal antibody responses were suppressed after inoculation at both 3 and 10 weeks. The degree of suppression appeared to be related to the level of BRSV-specific IgG 1 prior to inoculation. Reinoculation antibody responses were similar to those observed in colostrum-deprived calves, although not as high Virus isolation was more successful from lung lavage fluid than from nasal swabs for both colostrum-fed and colostrum-deprived calves. Colostrum-fed animals shed an approximately equal amount of virus in lung lavage fluid as did colostrum-deprived calves from day 3 to day 8 PI. No BRSV was reisolated after the second or third inoculations. Although the inoculation protocol was similar to that used previously, 10 which resulted in severe clinical signs, only mild signs of respiratory disease were produced in these calves. The experimental BRSV titer was thought to be too low, because naturally infected calves demonstrated stronger antibody responses to BRSV than did experimentally infected calves.
A later study by the same group examined the role of different inoculation protocols in priming airway mucosal and serum antibody responses against BRSV in calves with and without maternal antibodies. 30 The BRSV isolate in the inoculum (10 4 TCID 50 BRSV/ml) was identical to that used in the previous study. 29 The inoculum was confirmed by immunofluorescence to be free of BVDV. At 3 weeks of age, all calves were primed with ultraviolet light-exposed inoculum (10 4 TCID 50 BRSV/ml) by 1 of several routes (intranasal, intratracheal, intramuscular, or intranasal plus intratracheal). All calves were reinoculated at 3 months of age with 15 ml of original inoculum intratracheally and 5 ml intranasally for 4 consecutive days. Secretory antibody responses in the lung were similar to those found in nasal and eye secretions, as reported in a previous study. 29 After priming either by intranasal or combined intranasal/intratracheal routes, BRSV was isolated from lung lavage fluid and less often from nasal secretions. In contrast to the results of the previous study, 29 BRSV was more often isolated from colostrum-fed calves than from colostrum-deprived calves. None of the live-virus respiratory tract primed calves shed virus after challenge, and all developed mucosal and serum antibody memory responses. Virus was isolated from calves primed with killed (ultraviolet light exposed) BRSV, calves given live virus intramuscularly, and calves not primed. There appeared to be no correlation between serum neutralizing antibodies and protection. Reinoculation resulted in very minimal clinical signs of respiratory disease.
Another study examined the role of passive immunity in colostrum-deprived and colostrum-fed calves. 6 Colostrum was obtained from dairy cows vac-cinated twice with a BRSV vaccine prior to calving. Colostrum was collected at the first milking, pooled and stored at -20 C. The calves were given a field isolate of BRSV intranasally and intratracheally on days 3-6 of life. The intranasal inoculum contained 10 2.72 -10 3.8 TCID 50 BRSV/ml, and the intratracheal inoculum contained 10 4.8 -10 5.9 TCID 50 BRSV/ml. Control calves were sham inoculated with noninfected tissue culture fluids. Viral inoculum was screened for the presence of BVDV.
Colostrum, as the source of passive immunity, modified the severity of disease in colostrum-fed BRSVinoculated calves. There were significant differences between groups in PaO 2 and in percentage of pneumonic lung; the colostrum-deprived calves were more severely affected. Virus was isolated from nasal swabs of both colostrum-fed and colostrum-deprived calves. Gross lesions were observed in all lung lobes of colostrum-deprived BRSV-inoculated calves but were minimal in colostrum-fed calves. A cranioventral distribution predominated. BRSV antigen was detected by immunoperoxidase staining of lung sections only in colostrum-deprived BRSV-inoculated calves. Antigen-positive cells were identified in bronchiolar mucosal epithelium, bronchiolar and alveolar lumina, and alveolar linings. Only 1 of 6 colostrum-fed calves had histologic lesions that could be attributed to BRSV, whereas histologic lesions in colostrum-deprived BRSV-inoculated calves were characterized as moderate multifocal interstitial pneumonia, with moderate multifocal necrotizing or proliferative bronchiolitis. Multinucleate syncytial cells were evident in bronchioles and alveoli of 4 colostrum-deprived BRSV-inoculated calves. Although, it appears that a colostral factor modifies the severity of BRSV, the duration of protection was not demonstrated.
Experimental BRSV infections in lambs
Complement-fixing and neutralizing antibodies to RSV have been found in sheep sera, indicating the possibility of RSV as a pathogen in ovine respiratory disease. 8, 53 The virus has been isolated from sheep, but the disease has not been well characterized, although preliminary results suggest ovine RSV may be distinct from BRSV, as indicated from RNase A mismatch cleavage analysis. 19 These differences have been further supported in recent studies. 40 Studies were undertaken to determine if sheep were susceptible to BRSV. Experimental inoculation of lambs with BRSV resulted in production of only mild clinical respiratory disease.
Initial experimental studies used isolate 375 of BRSV (third passage) in inoculum containing 10 3.6 PFU/m1. 32 Inoculum was negative for BVDV. Colostrum-deprived lambs approximately 1 week of age were inoculated with 10 ml intratracheally and 10 ml intra-nasally. Three of 5 lambs developed an increased respiratory rate, increased rectal temperature, and decreased activity between days 3 and 5 PI. Interstitial pneumonitis was observed in all lung lobes of lambs necropsied on days 7, 9, and 11 PI. Virus was isolated from only 2 of 5 lambs, but all developed specific serum antibody titers by the time of necropsy.
The same researchers then inoculated 6 6-monthold colostrum-deprived feeder lambs with a BRSV isolate (232) recovered from lung of 1 of the previously infected lambs. 33 Twenty milliliters of the inoculum, containing 10 3.9 PFU/ml, was given intratracheally. Five of the 6 lambs developed mild respiratory disease characterized by depression, hyperpnea, and a 24-hour febrile response on day 3 PI. Lesions in these lambs were less severe than those in the younger lambs. 32 After inoculation, 5 of 6 lambs seroconverted; 1 lamb necropsied on day 3 PI only had a 2-fold increase in antibody titer. Virus was isolated from 5 of 6 lambs, initially from tracheal fluid and later from nasal secretions, suggesting that the lower respiratory tract was the site of primary viral replication. Although older lambs responded more rapidly and with higher antibody titers PI, they still became infected with BRSV, suggesting no age predisposition or resistance. The researchers stated that without secondary bacterial infection, RSV lesions may resolve and infections may go unnoticed.
The l-week-old lamb model was once again utilized by the same group to examine BRSV-associated respiratory tract lesions. 17 As before, only mild respiratory disease was produced, and lambs were necropsied on days 7, 9, 11, and 28 PI. Lesions on gross examination consisted of multiple hemorrhagic foci dispersed throughout all lung lobes of younger lambs and pale pink to gray foci in older lambs. Histopathologic changes were consistent with those observed in calves and consisted of necrosis of pulmonary epithelium in terminal airways and accumulation of cellular debris and mononucIear cells in terminal airways and alveoli. The importance of BRSV as a primary respiratory tract pathogen in sheep was questioned, and it was proposed that BRSV may be more important in compromising and predisposing the respiratory tract to secondary bacterial infections.
A study was undertaken to determine whether BRSV infection would potentiate Pasteurella haemolytica infection in lambs and to describe subsequent clinical and pathologic changes in these lambs. 2,3 Twenty-one 4-week-old colostrum-deprived lambs were inoculated intratracheally with P. haemolytica alone, BRSV alone, or both, with P. haemolytica given either 3 or 5 days after BRSV. Pasteurella haemolytica biotype A serotype 1, with a cell count of 3 x 10 7 CFU/ml, was administered in 5-ml aliquots and BRSV 232, con-taining 2.9 x 10 7 PFU/ml, was given as a 20-ml inoculum. Nine of 15 lambs inoculated with BRSV alone or before inoculation with P. haemolytica displayed decreased activity on day 3 PI, which worsened by days 4-5 PI, along with hyperpnea, dyspnea, and pyrexia. Lambs inoculated with P. haemolytica 5 days after primary RSV inoculation displayed more pronounced clinical signs than those inoculated at day 3. Control lambs did not display any signs of disease. Combined RSV-P. haemolytica challenge produced more severe and persistent disease than either agent did alone. Disease signs manifested by the combined challenge included pyrexia, lethargy, nasal discharge, hyperpnea, dyspnea, coughing, anorexia, loss of condition, and recumbency. Clinical signs, although mild, in lambs inoculated with BRSV alone were more pronounced than signs in lambs inoculated with P. haemolytica alone.
RSV was isolated from nasal secretions or respiratory tissue taken at necropsy from 8 of 15 lambs. Lesions in 3 of 4 lambs inoculated with BRSV alone included consolidated areas surrounded by emphysematous tissue, more, often in caudal lobes. Areas of consolidation and hemorrhage were observed in lungs of 2 of 4 lambs inoculated with P. haemolytica alone. Lambs inoculated with RSV and P. haemolytica (day 3) and euthanized 4 days after bacterial inoculation had discrete areas of consolidation and abscesses. Lambs euthanized 2 days after bacterial inoculation also had areas of consolidation. Lambs inoculated with P. haemolytica 5 days after BRSV inoculation had fibrinous pleuritis and small, multifocal consolidated areas with surrounding hemorrhage. The lesions were more prominent in those lambs necropsied 2 days after bacterial inoculation than in those necropsied 4 days after bacterial inoculation. Histologic lesions of lambs inoculated with RSV alone included a multifocal pneumonitis, slight to moderate bronchitis, bronchiolitis, and occasional multinucleated giant cells. All lambs inoculated with RSV and then P. haemolytica had multifocal areas of interstitial pneumonitis and pulmonary consolidation. These lesions were more severe than those in lambs associated with either agent alone. Viral antigen was detected by immunofluorescence, mainly in bronchial and bronchiolar epithelium and in alveolar walls. 1 Viral antigen was seen budding from the plasma membrane of ciliated and nonciliated epithelial cells of bronchi and bronchioles but not from pneumocytes. Cellular changes were more extensive in lambs inoculated with both RSV and P. haemolytica than in those inoculated with RSV alone. It was proposed that infection of epithelial cells of bronchi and bronchioles by RSV predisposes to infection by P. haemolytica.
Another group of researchers proposed to examine a more natural route of infection by aerosolization of BRSV. 59 Forty conventionally reared 6-month-old lambs, seronegative to RSV, were used. Twenty milliliters of inoculum (10 7 TCID 50 /ml) was prepared from the ATCC VR-794 isolate of BRSV at the third passage level. Thirty lambs were each inoculated over a 20-30-minute interval using 2 nebulizers with air pressure of 172.37 kPa at the external nares, allowing the lambs to freely inhale the inoculum. Control lambs were inoculated with tissue culture fluid in a similar procedure. Lambs were sequentially euthanized between days 2 and 40 PI. Mild disease response in inoculated lambs included pyrexia on day 4 PI and presence of a serous oculonasal discharge in some lambs. Virus was isolated from nasal swabs of inoculated lambs on a few occasions and from pulmonary tissue collected on day 2 PI from all inoculated lambs. All but 2 BRSV-inoculated lambs developed an antibody response; the earliest seroconversion occurred on day 6 PI; most antibody responses stabilized at a serum neutralization titer of 1:20. Positive immunofluorescence was identified in interalveolar septa, in some alveolar macrophages, and in occasional bronchiolar epithelium of BRSV-inoculated lambs only at days 2 or 4 PI. Only 2 BRSV-inoculated lambs had gross lesions, which consisted of multifocal areas of consolidation in cranial lung lobes observed at days 2 and 4 PI. Lambs euthanized between days 6 and 9 PI had lesions of bronchiolitis, whereas a mild alveolitis was observed in lambs euthanized from day 2 to day 18 PI. Ultrastructurally, thickened interalveolar septa, containing occasional necrosis of type I and II epithelial cells, were observed. Virus-like particles budding from the cell membrane were observed. Although clinical signs of respiratory disease were not pronounced, aerosol administration of BRSV in lambs successfully produced infection, virus replication, and respiratory tract disease. These same researchers then used 38 conventionally reared seronegative lambs and inoculated with BRSV alone, P. haemolytica alone, or both BRSV and P. haemolytica to evaluate potential virus-bacteria synergism. 60 Lambs were inoculated by a combined aerosol/intranasal route with 20 ml of viral (ATCC VR-794, 10 6 TCID 50 /ml) and/or 20 ml of bacterial (P. haemolytica biotype A, serotype 1, ovine origin, 8 x 10 8 CFU/ml) inocula. Pyrexia and oculonasal discharge were observed in all principal groups. In most lambs inoculated with both BRSV and P. haemolytica, depression and polypnea were also observed. Macroscopic lesions, consisting of firm, red, well-demarcated regions of consolidation with a cranioventral distribution, were observed only in groups inoculated with both BRSV and P. haemolytica. A suppurative bronchopneumonia was the predominant histopathologic change identified. BRSV and P. haemolytica were isolated from pulmonary tissue. Viral antigen was demonstrated via immunofluorescence within alveolar cells, some alveolar macrophages, and a few bronchiolar epithelial cells.
Seroconversion to BRSV was not demonstrated because most lambs were necropsied before serum neutralization titers could be detected (day 12 PI). Low concentrations of antibodies to BRSV and P. haemolytica were detected in some lung lavage samples collected at postmortem in both control and inoculated lambs, indicating a possible explanation for why all lambs receiving the viral-bacterial exposure did not develop disease. The presence of neutralizing antibodies in pulmonary secretions could have possibly inactivated virus and/or bacteria. Latex phagocytosis and Fc receptor assays were conducted on alveolar macrophages obtained postmortem, and decreased Fc receptor and latex phagocytosis were detected in lambs inoculated with BRSV and then P. haemolytica. As previously observed, 2 it appears that BRSV does facilitate P. haemolytica respiratory infections in conventionally raised immunocompetent lambs. Depressed alveolar ed in this study. macrophage function was document-Three lambs were inoculated with an ovine isolate (WSU83/1587) of RSV by a 4-day combined intranasal and intratracheal route. 9 The seventh passage inoculum (10 4.8 -10 5.0 TCID 50 /ml) was administered by the combined route (10 ml each) for 2 days and then 20 ml intranasally for the last 2 days. One lamb was used as a contact control animal.
Mild clinical signs in the inoculated lambs started on day 3 PI and included coughing, serous nasal discharge, and dullness. Lambs were necropsied on days 5, 6, 7, and 10 PI. Macroscopic lesions, consisting primarily of pulmonary consolidation in cranial lobes were observed only in virus-inoculated lambs. Two of 3 lambs necropsied also had pneumonic lesions in the middle and caudal lung lobes. Histopathol ogic changes consisted of bronchitis and bronchiolitis with epithelial hyperplasia, lymphocyte accumulations in the perivascular and peribronchiolar spaces, and thickening of alveolar septa. Immunoperoxidase staining for RSV antigen was positive in the bronchial, bronchiolar, and alveolar epithelial cells of challenged lambs necropsied on days 5 and 6 PI. Virus was isolated from either nasal swabs on day 4 PI and/or lung and bronchial lymph node samples at necropsy. Levels of antibody to RSV, measured by serum neutralization seroconversion in 2 of 3 challenged lambs.
, indicated
Utilization of a 4-day inoculation protocol only resulted in the production of mild respiratory disease. The isolation of virus from the nasal swabs indicated that the ovine RSV may replicate in the upper respi-ratory tract, which has not always been a consistent finding in lambs inoculated with BRSV. 3, 33 The researchers also felt the peribronchiolar and perivascular cellular infiltrations were more pronounced in lambs inoculated with the ovine isolate than in lambs inoculated with BRSV.
Another group pursued BRSV pathogenesis in conventionally reared lambs. 46 The 6-8-week-old BRSVseronegative lambs were inoculated intranasally (12 ml) and intratracheally (8 ml) with third passage viral inoculum (BRSV 66, 6.3 x 10 5 TCID 50 ). Control lambs were similarly exposed but with noninfected lamb testis cell cultures. Mild clinical signs of respiratory disease, consisting of nasal discharge, coughing, and pyrexia, were observed on days 5-9 PI. A disease scoring system, similar to that previously described for calves, 61 was utilized. All lambs possessed positive scores by day 7 PI, primarily resulting from increased bronchovesicular sounds. Isolation of BRSV from nasal swabs was accomplished between days 3 and 7 PI for 9 of 24 lambs. For all lambs euthanized between days 3 and 11 PI, BRSV was isolated from lung and tracheal tissue. Multifocal consolidated areas were identified in all lambs euthanized between days 5 and 11 PI. Lesions were more severe on day 8 PI and more pronounced in cranial and caudal lung lobes. There were fewer CD4 + lymphocytes and more CD8 + lymphocytes in lung lavage fluid from BRSV-infected lambs than in fluid from control lambs. Serum antibody first appeared on day 6 PI, and peak titers to BRSV were observed between days 14 and 21 PI.
The same research group used monoclonal antibodies to examine lymphocyte subpopulations from BRSVinoculated lambs and from clinically normal lambs. 49 The 6-8-week-old BRSV-seronegative lambs were inoculated according to the protocol utilized in the previous study. 46 Peripheral leukocyte counts of BRSVinfected lambs were significantly lower than those of control lambs. As in the previous study, CD4+ lymphocytes were decreased and CD8 + lymphocytes were increased in peripheral blood from infected lambs. By day 10 PI, the CD4:CD8 ratio was significantly decreased and was still depressed at days 14 and 21 PI. Although many viruses, including RSV, 45 may infect lymphocytes, it was not clear whether direct viral infection was responsible for the altered immunocompetence. The increase in CD8+ lymphocytes possibly indicated recovery from viral infections, whereas the decrease in CD4+ lymphocytes may indicate immunosuppression and increased susceptibility to other pathogens.
The same inoculation protocol was used to measure lymphocyte responses to phytohaemagglutinin. 47 All BRSV-inoculated lambs seroconverted by day 14 PI. BRSV significantly depressed transformation re-sponses of CD4-enriched lymphocytes up to day 10 PI Clinical disease, pathology, pulmonary function, and airway responsiveness were evaluated in lambs inoculated with an isolate of ovine RSV. 62 Inocula were produced from first-passage virus, containing equal volumes of 10 3.5 median cell culture infective dose and was administered intratracheally. Experimentally induced disease was mild. Mild pyrexia was observed in only 2 of 9 RSV-inoculated lambs during the first week PI. By the third week PI, daily weight gains were greater in the control than in the infected group. Open lung biopsies were taken at weeks 1 and 3 PI, and abnormalities observed included bronchiolar epithelial hyperplasia, eosinophilic cytoplasm, nuclear pyknosis, lymphoid hyperplasia, and multinucleated cells. Pulmonary function tests revealed similar C dynamic compliance in both groups and increased R long resistance and significantly reduced functional residual capacity in infected lambs. Histamine, carbachol, and citric acid were used to test airway responsiveness, and no statistical difference was noted between RSV-inoculated and control lambs. In general, seroconversion to RSV occurred in challenged lambs but not in control lambs. Disappointing results of this lamb model included lack of severe disease and the absence of the airway hyperresponsiveness that is commonly observed after natural cases of pediatric HRSV infection. 43 The efforts of these researchers may also have been compromised by the absence of standardized protocols for pulmonary function testing in sheep.
Evaluation of the effect of RSV infections on reflex apnea was undertaken in 2-week-old lambs. 34 Apnea is thought to be important in sudden infant death syndrome? Lambs were inoculated through a low tracheostomy site with 4 ml of BRSV stock strain A51908 with a titer of 5 x 10 5 PFU/ml. The researchers did demonstrate that laryngeal chemoreflex apnea, elicited by the application of water onto the laryngeal mucosa, was exaggerated during BRSV infection in lambs. In addition, the only clinical signs of respiratory disease observed were slight nasal and tracheal discharges. No differences in PaO 2 , PaCO 2 , or pH were identified between infected and control lambs. Virus was isolated from only 1 of 6 lambs on day 5 PI, and 3 of 6 lambs displayed an increase in serum neutralizing antibody titer to BRSV at weeks 3-6 PI.
A previously described lamb challenge model 46 was utilized to characterize the humoral immune response produced by BRSV infection. 48 An ELISA was used to titrate virus-specific IgG, IgM, and IgA levels in nasal secretions, lung lavage fluids, and serum samples PI. Mild clinical signs of respiratory disease, BRSV seroconversion, and positive virus isolation attempts indicated that successful experimental infection had oc-curred. Virus-specific antibodies did not appear in lung lavage fluid until day 5 PI. Virus-specific IgA antibodies first appeared in nasal secretions on day 7 PI, with IgM and IgG antibodies appearing later. Virus-specific IgM and IgA antibodies were detected in serum by day 6 PI, IgG antibodies were detected by days 6-10 PI, and peak titers occurred by days 14-21 PI in BRSVinfected lambs.
Experimental HRSV infection in lambs
Conventionally raised lambs seronegative for HRSV were used to create a model for HRSV infection in human infants. 31 Six lambs were inoculated either intratracheally or intranasally using HRSV-18577, type B strain, in 2 ml of inoculum containing 1 x 10 7 PFU/ ml. Eight control lambs were inoculated intratracheally with noninfected control lysate. Intratracheal inoculation more consistently produced clinical signs (tachypnea, pyrexia) of respiratory disease then did intranasal inoculation, and both inoculated groups had more nasal fluid protection than did the control lambs. By week 2 PI, a 6-fold or greater rise in serum neutralizing antibody tissue occurred only in virus inoculated groups. Virus was cultured from the nasopharynx 6 times more frequently from intranasally inoculated lambs than from intratracheally inoculated lambs starting on day 3 PI. All lambs were necropsied at 4 weeks PI, and no gross or microscopic lesions were identified that were compatible with HRSV infection. The lack of histologic findings may be due to the fact that the lambs were euthanized late (28 day PI) in the disease process. Even so, this lamb model could be used to study the pathogenesis of HRSV infections in calves.
Discussion
Several studies of experimental BRSV inoculations were not successful in producing clinical signs and/or lesions of severe respiratory tract disease. 25, 26, 36, 38, 41, 54 Experimental inoculations of BRSV that produced clinical signs were characterized mostly by pyrexia of some degree, serous nasal discharge, conjunctivitis and./ or lacrimation, mild cough, and increased or abnormal lung sounds. Less commonly observed were abnormal breathing patterns, anorexia, depression, and lethargy. Rechallenge of calves most often resulted in no clinical signs of respiratory disease. 14, 29, 37 The most common macroscopic lesion described was consolidated lung, usually with a cranial distribution. Emphysema and hemorrhage were occasionally observed. Histopathologic changes included peribronchiolar lymphomononuclear cellular infiltrates, varying degrees of bronchiolitis, interstitial pneumonia, and syncytial cells. Alveolitis and bronchitis were also described, but less commonly. Ultrastructural findings included the presence of viral nucleocapsids and bud-ding virions in intratracheal and bronchial ciliated and nonciliated epithelial and mucous cells. 1, 11, 17 Virus isolation was accomplished more often from upper respiratory than lower respiratory samples, which in some cases appeared related to the number of samples. In other studies, pulmonary samples were taken at necropsy weeks after inoculation, which would account for the low rate of positive virus isolation. Dexamethasone treatment resulted in increased amount and time of viral shedding and more severe disease. Immunofluorescence allowed for relatively fast and simple identification of viral antigen, usually present around day 3 PI and peaking by about day 10 PI. Positive immunofluorescence occurred most commonly in bronchiolar epithelial cells and bronchiolar and alveolar exudate, 12,35,56 with positive results also from nasopharyngeal samples. 12, 34 Immunoperoxidase staining for the presence of BRSV antigen produced positive results in bronchiolar mucosal epithelium, bronchiolar and alveolar lumina, and alveolar linings throughout the lung. 6, 9, 14 This technique did appear to be more sensitive than immunofluorescence or ultrastructural detection because virus or antigen detected by these methods was not commonly identified in alveoli.
Production of antibody to BRSV as measured by serum neutralization was present by days 6-7 PI and generally was expressed as relatively low titers. Single radial hemolysis was not as commonly utilized. Neutralizing antibody appeared as early as day 3 PI. The presence of maternal antibody or circulating serum antibody did not result in any exacerbation of disease 29, 30, 37 and nasal secretory antibody appeared to offer protection from severe BRSV disease in 1 study. 37 The presence of maternal antibody in later studies did appear to decrease the severity of BRSV disease. 6 Interferon was measured in few studies; 21 it appeared very early PI, and levels decreased by day 6 PI. The type of interferon present was not characterized.
Calves appear to be the model best suited for RSV infection because they are natural hosts for the disease, and neonates are the primary age group affected by RSV. Calves are born agammaglobulinemic, which allows for the control of transfer of maternal antibody to the calf via colostrum and/or plasma. The effect of passive transfer of maternal antibodies can be regulated to study calves with a total lack of antibody protection for BRSV or, at the other extreme, to examine the effect of hyperimmunization with maternal antibody specific for BRSV. Because passive immunity may affect disease severity and efficacy of vaccination for RSV, it is important that the immune status of the animal be controlled. Repeat infections with RSV occur in calves, as in humans. 53 Recurrent infections appear to be less severe and may be related to the shorter duration of immunity in the upper versus the lower respiratory tract. 53 The ability to reproduce severe respiratory disease in calves with BRSV has been documented 6,10, 35 Lambs can be inoculated with BRSV, ovine RSV, and HRSV but do not demonstrate the severity of clinical signs or lesions that are observed in calves. 3, 9, 17, [31] [32] [33] 46, 59 Concurrent inoculation with pasteurella haemolytica did result in more severe disease in lambs. [1] [2] [3] Both calves and lambs have been inoculated with HRSV, resulting in the production of mild respiratory disease 26, 31, 58 Because calves suffer from natural BRSV infection, it would seem logical to inoculate using the same virus. Because of the similarities of pathogenesis with HRSV and BRSV infections, results of studies in calves may be relevant to research with humans.
There were differences in inocula used in experimental studies of RSV infections. Volume, titer, and pathogenicity or passage level determine effectiveness of the challenge model. It is imperative to screen for the presence of BVDV in fetal calf serum and BRSV isolates 22, 39 to ascertain that BVDV in the inoculum is not responsible for the severity of disease produced. Many early studies that demonstrated clinical signs of respiratory diseases failed to mention any concern for the role of BVDV and these signs. 25, 26, [36] [37] [38] 42, 50 Many initial studies failed to utilize control calves and to inoculate with uninfected tissue culture medium. 25, 26, 42, 50 Inoculation via 1 route or at 1 time has not been demonstrated to be sufficient to produce severe signs of respiratory disease.
The importance of method of inoculation was demonstrated by those studies using a combined intranasal/ intratracheal route over multiple days, 10 which produced the most severe clinical signs and lesions.
Host factors, including age, immune status, pulmonary defense mechanisms, presence of concurrent infections, and stress, may all determine the outcome of respiratory infections. By thoroughly assessing all animals and eliminating most of these variables, a more uniform population of experimental calves can be obtained.
Experimental BRSV inoculation does not exactly duplicate naturally occurring disease. However, it does allow for demonstration of clinical signs and lesions that closely resemble those produced by natural RSV disease. Utilization of uniform animal models and adherence to uniform inoculation protocols may enhance research in experimental BRSV infections; it is difficult to make comparisons among studies that use different protocols. An excellent model appears to include colostrum-deprived calves less than 1 week of age inoculated with a low passage (5 or less) BRSV isolate (approximately 10 5 TCID 50 /ml) given in 2-ml aliquots intranasally and intratracheally over a 4-day period.
